Humacyte, Inc. Unsecured Debt, Current
Humacyte, Inc. (HUMA) had Unsecured Debt, Current of $0 as of 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current
us-gaap:UnsecuredDebtCurrent · last filed 2026-03-27
- 2025-12-31: Unsecured Debt, Current $0.00.
- 2025-09-30: Unsecured Debt, Current $3.07M.
- 2025-06-30: Unsecured Debt, Current $2.12M.
- 2025-03-31: Unsecured Debt, Current $1.69M.
| Period end | Unsecured Debt, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 |
| 2025-09-30 | $3.07M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.12M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.69M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $885.00K 10-K · filed 2026-03-27 |
| 2020-12-31 | $2.45M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |